A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 388 participants.

Also called NCT01894568

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 388 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01894568
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan, South Korea, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01894568. Randomized; no masking; primary purpose treatment. Start 2013-07 (registry gives no type); primary completion 2015-04 (actual). Results posted on 2019-03-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Insulin Peglispro
Intervention (Drug)
Insulin Glargine
Intervention (Drug)
Oral Antihyperglycemic Medications (OAMs)
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01894568
Content hash
79103f0691ec0f19340502de69586c91f8a0bd14884b39889d37d94a446d364b